Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : BVF Partners
Deal Size : $128.0 million
Deal Type : Financing
Diagonal Launches with $128 Million to Develop Agonist Antibodies for Diseases
Details : The financing proceeds fund the clinical advancement of Diagonal's lead program, a TGF beta receptor agonist for the treatment of hereditary hemorrhagic telangiectasia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 04, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : BVF Partners
Deal Size : $128.0 million
Deal Type : Financing